116 Evaluating the introduction of subcutaneous natalizumab to a cohort of patients with multiple sclerosis
Conclusion Subcutaneous natalizumab is a well-tolerated alternative to the intravenous infusion. In this cohort of patients, the majority were satisfied with switching, finding the SC injection more convenient, although some patients reported more pain especially when delivered in the arm. A major benefit to patients and staff is reduced delivery time, improving access to valuable infusion space. Monitoring will be reduced further to 15 minutes, once patients have received 6 injections.